Respuesta (5): Ver Todas

“This immediately was practice changing,” Misty Shields, MD, PhD, emphasized. “This is an area of vulnerability for patients who have extensive- stage disease , have had a brisk or meaningful response after induction chemoimmunotherapy, and then switched to immunotherapy and relapsed. Lurbinectedin plus atezolizumab is a helpful option to add for patients with extensive-stage disease in the maintenance setting to help prevent that high risk of relapse we see with immunotherapy alone.”

Respuesta (5): Ver Todas

Shifting First-Line Maintenance Strategies Raise Questions in ES-SCLC

Data from the phase 3 IMforte trial (NCT05091567) presented at ASCO 2025 showed that in patients with ES-SCLC whose disease did not progress after first-line induction therapy with carboplatin, etoposide, and atezolizumab, first-line maintenance therapy with the combination of lurbinectedin (Zepzelca) and atezolizumab significantly improved both PFS and OS compared with atezolizumab monotherapy (Table 1).6 The median PFS was 5.4 months (95% CI, 4.2-5.8) with lurbinectedin plus atezolizumab (n = 242) vs 2.1 months (95% CI, 1.6-2.7) with atezolizumab alone (n = 241; stratified HR, 0.54; 95% CI, 0.43-0.67; 2-sided P < .0001). The median OS in these respective arms was 13.2 months (95% CI, 11.9-16.4) compared with 10.6 mont

Respuesta (10): Ver Todas

Todavía está por demostrar que tarlatamb sea mejor que Lurbi en el mundo real, no con un ensayo hecho a medida y comparándolo con topotecan mayormente...